| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd4cc2aacf8b71b6892dd007aa277497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67aa3bc75203266389dcde6a7cb83250 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate |
2018-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b960cbbe621be059d53221b8c8743d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dab9ec65a16bc26d42e72f3980de063a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b88efd0496e913f821ce870d7b19ada
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_218da94ddd9528139293208c525b924b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba1ff8ee6e4b2f90aa23f5a991a443ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd639bc5de3b3a243ecc6f2d82cffd92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30eeea931deab188dfba36573971870a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a50d507090d35cf69ffefba98ae37d0 |
| publicationDate |
2020-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110643694-A |
| titleOfInvention |
Application of circular RNAcircPOLR2A in systemic lupus erythematosus detection of markers and preparation of therapeutic drugs |
| abstract |
The invention belongs to the field of biomedicine, and particularly relates to the application of circular RNA circPOLR2A in systemic lupus erythematosus detection markers and preparation of therapeutic drugs. In the present invention, the circPOLR2A gene is used as a marker for diagnosing systemic lupus erythematosus, and the circular RNA is stable in cells and is not easily degraded, so that the diagnosis of systemic lupus erythematosus is more accurate and rapid. The gene expression product thereof is used as a drug molecule for the preparation of systemic lupus erythematosus, and provides a new therapeutic approach for the treatment of systemic lupus erythematosus. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020173171-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113710816-A |
| priorityDate |
2018-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |